Noninvasive Prenatal Testing Market Set for Explosive Growth
|
By HospiMedica International staff writers Posted on 21 Jan 2014 |
|
The global noninvasive prenatal testing (NIPT) market is expected to grow more than ten-fold in the next five years. These are the latest findings of Transparency Market Research (Albany, NY, USA), a global information and research provider.
NIPT, the noninvasive genetic screening test for common chromosomal abnormalities (trisomy 21, trisomy 18, trisomy 13, monosomy X, etc.) can detect the presence of abnormalities in fetuses of pregnant women as early as 9–10 weeks of gestation, with some of the most commonly detected chromosomal aneuploidies include Down syndrome, Edwards syndrome, Patau syndrome, and monosomy X. The market is also evolving rapidly due the advantages it offers over conventional prenatal screening and diagnostic methods such as maternal serum screening, nuchal translucency (NT) scan, amniocentesis, and chorionic villus sampling (CVS). These advantages include safety, accuracy, and no risk of miscarriage.
MaterniT21 PLUS, verifi, Harmony, Panorama, NIFTY, PrenaTest, and BambniTest are currently the commercially available NIPTs, all based on the direct analysis of cell-free fetal DNA in the maternal blood. In 2012, MaterniT21 (a proprietary product of Sequenom) accounted for the largest share (36.6%) of the market in terms of revenue, owing to the fact that it was the first mover in the market place. During the forecast period 2013 to 2019, it is likely to lose some of its share due to increasing market penetration by other, aforementioned NIPTs such as Panorama and verify.
Almost every company in this market is adopting the same business model of marketing their tests via alliances with hospitals, diagnostic laboratories, and physician offices. The increasing penetration by test developers in European, Asia-Pacific, and Middle East countries indicates promising growth in the near future. Sequenom (San Diego, CA, USA), Verinata Health (Redwood City, CA, USA), Ariosa Diagnostics, and Natera (San Carols, CA, USA), are the leading companies engaged in providing noninvasive prenatal tests worldwide.
The global NIPT market was valued at USD 220 million in 2012 and is expected to grow at a compound annual growth rate (CAGR) of 37.6% from 2013 to 2019, to reach an estimated value of USD 3.62 billion by 2019. Geographically, North America was the largest regional market in 2012, with a market share of 64.5% of the total revenue generated globally, followed by Europe.
Related Links:
Transparency Market Research
Sequenom
Verinata Health
NIPT, the noninvasive genetic screening test for common chromosomal abnormalities (trisomy 21, trisomy 18, trisomy 13, monosomy X, etc.) can detect the presence of abnormalities in fetuses of pregnant women as early as 9–10 weeks of gestation, with some of the most commonly detected chromosomal aneuploidies include Down syndrome, Edwards syndrome, Patau syndrome, and monosomy X. The market is also evolving rapidly due the advantages it offers over conventional prenatal screening and diagnostic methods such as maternal serum screening, nuchal translucency (NT) scan, amniocentesis, and chorionic villus sampling (CVS). These advantages include safety, accuracy, and no risk of miscarriage.
MaterniT21 PLUS, verifi, Harmony, Panorama, NIFTY, PrenaTest, and BambniTest are currently the commercially available NIPTs, all based on the direct analysis of cell-free fetal DNA in the maternal blood. In 2012, MaterniT21 (a proprietary product of Sequenom) accounted for the largest share (36.6%) of the market in terms of revenue, owing to the fact that it was the first mover in the market place. During the forecast period 2013 to 2019, it is likely to lose some of its share due to increasing market penetration by other, aforementioned NIPTs such as Panorama and verify.
Almost every company in this market is adopting the same business model of marketing their tests via alliances with hospitals, diagnostic laboratories, and physician offices. The increasing penetration by test developers in European, Asia-Pacific, and Middle East countries indicates promising growth in the near future. Sequenom (San Diego, CA, USA), Verinata Health (Redwood City, CA, USA), Ariosa Diagnostics, and Natera (San Carols, CA, USA), are the leading companies engaged in providing noninvasive prenatal tests worldwide.
The global NIPT market was valued at USD 220 million in 2012 and is expected to grow at a compound annual growth rate (CAGR) of 37.6% from 2013 to 2019, to reach an estimated value of USD 3.62 billion by 2019. Geographically, North America was the largest regional market in 2012, with a market share of 64.5% of the total revenue generated globally, followed by Europe.
Related Links:
Transparency Market Research
Sequenom
Verinata Health
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Medical Examination & Procedure Light
Vega 80
Multi-Chamber Washer-Disinfector
WD 390
Latest Business News
- AI Software Combines Nodule Detection and Diagnosis for Lung Cancer Screening
- AI Care Platform Adds Quantitative MRI Analysis for Multiple Sclerosis
- Danaher Completes Acquisition of Masimo to Expand Patient Monitoring Capabilities
- Endologix Adds FDA-Cleared Peripheral Thrombectomy System
- Artivion Adds FDA-Approved NEXUS System to Aortic Arch Portfolio
- Olympus Partnership Aims to Expand Access to Robot-Assisted Endoscopic Therapy
- Johnson & Johnson Launches AI-Driven Cardiac Mapping System
- Proximie Advances AI-Driven Intelligent Operating Rooms with NVIDIA Collaboration
- GE HealthCare, DeepHealth Expand AI Breast Imaging Collaboration
- Sinocare Presents AI-Driven Integrated Digital Health Solutions at CMEF
- GE HealthCare and Medtronic Expand Alliance with Intraoperative Imaging Integration
- New Partnership Advances Physical AI into Perioperative Workflows
- External Liver Assist System Receives FDA RMAT Designation
- New Partnership Expands Access to Predictive Tool for Patient Monitoring
- GE HealthCare Leads Major European Initiative to Advance Cardio-Oncology Care
- Medtronic and GE HealthCare Broaden Alliance Across Monitoring and Care Solutions
Channels
Artificial Intelligence
view channel
Collaborative AI System Improves Medical Diagnostic Accuracy
Hospitals face a persistent trade-off when deploying artificial intelligence for diagnosis. Broad “generalist” models handle many tasks but often lack disease-specific precision. Narrow “specialist” models... Read more
AI-Powered Brain-Body Interface Supports Movement and Sensation Recovery
Neurological injuries such as stroke and spinal cord trauma frequently leave patients with profound motor and sensory deficits that limit independence. Rehabilitation may restore some movement, but recovery... Read more
Critical Care
view channel
Wearable Sweat Test Simplifies Cystic Fibrosis Diagnosis
Cystic fibrosis is a genetic disease that disrupts digestion and breathing. Diagnosis depends on sweat chloride testing that is typically limited to accredited centers and specialized laboratories.... Read more
New Risk Calculator Identifies Heart Disease Earlier in Postpartum Women
Cardiovascular disease in women often goes unrecognized until midlife, and standard risk calculators were built for older populations. Complications during pregnancy are linked to later heart disease,... Read more
Surgical Techniques
view channel
New Implant Provides Sustained Localized Therapy for Ovarian Cancer
Ovarian cancer is often diagnosed at advanced stages because symptoms such as bloating, pain, and pelvic pressure are nonspecific. Standard care relies on surgery and systemic therapy, yet tools for targeted... Read more
Combined Phage and Microbiota Therapy May Reduce Recurrent Urinary Tract Infections
Recurrent urinary tract infections (rUTIs) are frequent relapses of urinary infections that persist despite standard therapy. They increase morbidity, expose patients to repeated antibiotic courses, and... Read more
Patient Care
view channel
AI Avatar Doctor Improves Patient Understanding Before Radiotherapy
Radiation oncology consultations require patients to grasp complex concepts quickly, yet anxiety and information overload often undermine understanding and informed consent. Poor comprehension can also... Read more
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Medical Imaging
view channel
MRI-Guided Ultrasound Method Advances Targeted Treatment of Gliomas
Gliomas, the most common primary brain tumors in adults, include glioblastoma, the deadliest form of brain cancer. Drug delivery is hampered by the brain’s blood-brain barrier, limiting treatment efficacy... Read more
AI Accelerates Individualized Dosimetry for Prostate Cancer Treatment
Radiopharmaceutical therapy is an injected cancer treatment that delivers radiation through the body while selectively targeting tumors. In prostate cancer, current dosing remains largely uniform despite... Read more
Health IT
view channel
Short Digital Training Program Improves Motor Function in Parkinson’s Disease
Parkinson's disease causes motor symptoms that interfere with movement and daily activities. Drug treatment is standard care, yet additional approaches are needed to target motor control.... Read more
New Cloud Platform Streamlines Capsule Endoscopy Workflow and Reporting
Capsule endoscopy programs depend on coordinated acquisition, review, and reporting to support gastrointestinal services. Managing these activities across practices and health systems requires reliable... Read more
Point of Care
view channel
Rapid Onsite Testing Reduces Emergency Department Transfers in Long-Term Care
Respiratory infections in long-term care residents frequently trigger emergency department transfers that strain hospital capacity and expose frail patients to additional risks. Turnaround delays from... Read more
